Aclaris Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Aclaris Therapeutics, Inc. (ACRS) had Lessee, Operating Lease, Liability, to be Paid, Year One of $711.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $711.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $694.00K.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $766.00K.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $919.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $711.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $694.00K 10-K · filed 2025-02-27 |
| 2023-12-31 | $766.00K 10-K · filed 2024-02-27 |
| 2022-12-31 | $919.00K 10-K · filed 2023-02-23 |
| 2021-12-31 | $949.00K 10-K · filed 2022-02-24 |
| 2020-12-31 | $924.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |